Earnings Call · Q1 FY2022·2022-05-10

Q1 22EPS -9.92%·Rev n/aQ4 21EPS -56.25%·Rev n/aQ3 21EPS +3.87%·Rev n/aQ2 21EPS -52.94%·Rev n/a⚠ consensus missing

INOVIO PHARMACEUTICALS, INC. INO

Ben Matone — Senior Director of Investor Relations

Jacqueline Shea — President and CEO

Dave Liebowitz — Unclear, likely Senior Executive or Scientific Officer

Jeffrey Skolnik — Unclear, likely Senior Executive or Scientific Officer

Peter Kies — Chief Financial Officer

+5.1%1d on move date+4.8% vs SPY3d−20.7%5d−20.3%

Research tier

Behavioral profile computed for 5 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more INO calls or request research access.

More INO calls Browse calls Request research access